Overcoming cetuximab resistance in HNSCC: The role of AURKB and DUSP proteins

被引：54
|
作者：
Boeckx, Carolien [1 ]
de Beeck, Ken Op [1 ,2 ,3 ]
Wouters, An [1 ]
Deschoolmeester, Vanessa [1 ]
Limame, Ridha [1 ]
Zwaenepoel, Karen [4 ]
Specenier, Pol [1 ,5 ]
Pauwels, Patrick [1 ,4 ]
Vermorken, Jan B. [1 ,5 ]
Peeters, Marc [1 ,5 ]
Van Camp, Guy [2 ,3 ]
Baay, Marc [1 ]
Lardon, Filip [1 ]
机构：
[1] Univ Antwerp, CORE Antwerp, Lab Canc Res & Clin Oncol, Antwerp, Belgium
[2] Univ Antwerp, Ctr Med Genet, Dept Biomed Sci, Antwerp, Belgium
[3] Univ Antwerp Hosp, Antwerp, Belgium
[4] Univ Antwerp Hosp, Dept Pathol, Antwerp, Belgium
[5] Univ Antwerp Hosp, Dept Med Oncol, Antwerp, Belgium
来源：
CANCER LETTERS | 2014年 / 354卷 / 02期
关键词：
Head and neck squamous cell carcinoma; Anti-EGFR therapy; Cetuximab resistance; Dual-specificity phosphatase 5 and 6; Aurora kinase B; Nano Pro 1000; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; APIGENIN INDUCES APOPTOSIS; NECK-CANCER; COLORECTAL-CANCER; PANCREATIC-CANCER; MESENCHYMAL TRANSITION; AURORA KINASES; MONOCLONAL-ANTIBODY;
D O I：
10.1016/j.canlet.2014.08.039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Unraveling the underlying mechanisms of cetuximab resistance in head and neck squamous cell carcinoma (HNSCC) is of major importance as many tumors remain non-responsive or become resistant. Our microarray results suggest that "resistant" cells still exhibit RAS-MAPK pathway signaling contributing to drug resistance, as witnessed by low expression of DUSP5 and DUSP6, negative regulators of ERK1/2, and increased expression of AURKB, a key regulator of mitosis. Therefore, interrupting the RAS-MAPK pathway by an ERK1/2 inhibitor (apigenin) or an AURKB inhibitor (barasertib) might be a new strategy for overcoming cetuximab resistance in HNSCc. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：365 / 377
页数：13
相关论文
共 50 条
  • [21] Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC
    Yao, Yanli
    Wang, Yujue
    Chen, Lan
    Tian, Zhen
    Yang, Guizhu
    Wang, Rui
    Wang, Chong
    Wu, Qi
    Wu, Yaping
    Gao, Jiamin
    Kang, Xindan
    Duan, Shengzhong
    Zhang, Zhiyuan
    Sun, Shuyang
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [22] Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC
    Yanli Yao
    Yujue Wang
    Lan Chen
    Zhen Tian
    Guizhu Yang
    Rui Wang
    Chong Wang
    Qi Wu
    Yaping Wu
    Jiamin Gao
    Xindan Kang
    Shengzhong Duan
    Zhiyuan Zhang
    Shuyang Sun
    Signal Transduction and Targeted Therapy, 7
  • [23] Role of Src family kinases in acquired resistance to cetuximab
    Wheeler, Deric L.
    Ghia, Amol J.
    Kruser, Tim J.
    Armstrong, Eric A.
    Nechrebecki, Meghan
    Huang, Shyh-Min
    Harari, Paul M.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3397S - 3398S
  • [24] The role of DUSP2 in drug resistance in acute lymphoblastic leukemia
    Syed, F.
    Duran, P. Ayuda
    Hanes, R.
    Jallad, M. A.
    Majeed, W. M.
    Enserink, J. M.
    Anangi, B.
    Johansen, B.
    Kildalsen, H.
    Cascorbi, I.
    Seternes, O. M.
    Bruckmueller, H.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2024, 397 : S24 - S24
  • [25] Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance
    Wang, Jing-Quan
    Yang, Yuqi
    Cai, Chao-Yun
    Teng, Qiu-Xu
    Cui, Qingbin
    Lin, Jun
    Assaraf, Yehuda G.
    Chen, Zhe-Sheng
    DRUG RESISTANCE UPDATES, 2021, 54
  • [26] Overcoming cetuximab resistance in KRAS mutant colorectal carcinoma through HSP90 inhibition
    Ellegast, J.
    Scharrer, J.
    Scholl, C.
    Froehling, S.
    ONKOLOGIE, 2011, 34 : 247 - 247
  • [27] Overcoming Multidrug Resistance in Cancer Using Targeted Chimeric Proteins
    Grodzovski, Inna
    Lorberboum-Galski, Haya
    CLINICAL IMMUNOLOGY, 2009, 131 : S71 - S71
  • [28] ROLE OF MET AND RON ACTIVATION IN CETUXIMAB RESISTANCE IN COLORECTAL CANCER
    Graves-Deal, Ramona
    Bogatcheva, Galina
    Damalanka, Vishnu C.
    Klampfer, Lidija
    Janetka, James W.
    Coffey, Robert J.
    Singh, Bhuminder
    GASTROENTEROLOGY, 2021, 160 (06) : S593 - S593
  • [29] Role of MET signaling in cetuximab resistance and generation of an imaging biomarker to identify MET-driven cetuximab resistance in colorectal cancer
    Jones, Vivian T.
    Graves-Deal, Ramona
    Jeon, Kyuok
    Rosenberg, Adam J.
    Cao, Zheng
    Bogatcheva, Galina T.
    Harmych, Sarah J.
    Higginbotham, James N.
    Kim, Kwangho
    Janetka, James W.
    Sulikowski, Gary A.
    Singh, Bhuminder
    CANCER RESEARCH, 2023, 83 (07)
  • [30] The role of photodynamic therapy in overcoming cancer drug resistance
    Spring, Bryan Q.
    Rizvi, Imran
    Xu, Nan
    Hasan, Tayyaba
    PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES, 2015, 14 (08) : 1476 - 1491
12345